Loading clinical trials...

A Trial of NT-I7 in COVID-19 (SPESELPIS) | Clinical Trials | Clareo Health

TERMINATEDPHASE1

A Trial of NT-I7 in COVID-19 (SPESELPIS)

A Double-blind, Randomized, Placebo-controlled, Phase 1, Single-dose, Dose-escalating Trial of Long-acting Recombinant Human IL-7 (NT-I7) for COVID-19

NCT04501796•NeoImmuneTech

View on ClinicalTrials.gov

Summary

The main purposes of this study is to determine the following in participants with mild coronavirus disease 2019 (COVID-19): * Safety of a single dose of NT-I7 * The immunological effects of NT-I7 on peripheral lymphocyte counts in COVID-19 patients.

Detailed Description

This is a multisite, double-blind, randomized, placebo-controlled, dose-escalating, phase 1 trial of NT-I7 with standard of care (SOC) versus placebo with SOC to evaluate the safety and efficacy of NT-I7 in adults with mild coronavirus disease 2019 (COVID-19). After determination of eligibility and baseline assessment, a single dose of the study agent (NT-I7 or placebo) will be administered after 1:1 randomization, along with SOC. Research blood collection will occur at baseline, days 3, 7, 14, 30, 60 and 90 days after administration. Primary and secondary evaluations will include assessment of adverse events (AEs), absolute lymphocyte count (ALC), and trajectory of other lymphocytes subsets: CD4, CD8, natural killer (NK), B, and mucosal-associated-invariant T (MAIT) cells. The final study visit will be at day 90 after the study agent administration. The investigators hypothesize that NT-I7 is safe for administration and preserves lymphocyte homeostasis in patients with mild COVID-19.

Eligibility

Age

19 - 75 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Individuals must meet all of the following criteria to be included in the study:
•Laboratory-confirmed SARS-CoV-2 infection as determined by either a documented positive molecular assay/ other commercial or public health assay in any specimen collected \< 5 days prior to screening or a documented positive molecular assay ≥ 5 days prior to screening and confirmed by polymerase chain reaction (PCR) at screening.
•Illness of any duration with oxygen saturation \> 93% at room air, heart rate ≤ 100 beats per minute at rest, and no evidence of respiratory distress with respiration rate \< 20 breaths per minute.
•Able to provide informed consent.
•Aged ≥ 19 and ≤ 75 years.
•Absolute Lymphocyte Count \<1,500 lymphocytes/µL.
•Avoid becoming pregnant or impregnate a partner through 90 days after study agent administration. Females must agree to 2 methods of contraception, and males to at least one method of contraception.
•Not participate in any other clinical trial for an investigational therapy through day 30.

Exclusion Criteria

•Moderate to severe hypoxic respiratory failure requiring supplemental oxygen at rest, mechanical ventilation, ECMO, or any other noninvasive ventilation modality.
•CRP \>15 mg/L or D-dimer \> 0.75 µg/mL.
•Estimated glomerular filtration rate (eGFR) \< 40 mL/min/1.73m2, or requiring dialysis.
•AST/ALT \> 3-times ULN, or total bilirubin \> 1.5 times ULN (except if due to Gilbert's syndrome).
•Pregnancy or breastfeeding.
•Use of systemic corticosteroids or immunomodulant within 4 weeks prior to screening.
•Receipt of an investigational agent or investigational use of a licensed agent within 16 weeks prior to screening.
•HIV infection or underlying history of known or unknown primary or acquired immunodeficiency associated with lymphopenia and/or recurrent opportunistic infections.
•Autoimmune disease requiring systemic treatment EXCEPT for vitiligo or endocrine disease (such as diabetes, thyroid disease, and adrenal disease) controlled by replacement therapy.
•Malignancy requiring treatment 1 year prior to screening.

Locations (2)

Nih/Niaid

Bethesda, Maryland, United States

University of Nebraska Medical Center

Omaha, Nebraska, United States

Key Dates

Start Date

November 27, 2020

Primary Completion Date

July 21, 2021

Completion Date

February 23, 2023

Last Updated

July 14, 2023

Enrollment

ACTUAL participants

Conditions

COVID-19

Interventions

Double-Blind NT-I7

DRUG

Double-Blind Placebo

DRUG

A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes

NCT07221162

COVID-19

View study

RECRUITINGNA

Improving Post COVID-19 Syndrome With Hyperbaric Oxygen Treatments

NCT06082518

Post COVID-19 ConditionPost-COVID-19 Syndrome+4 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 14, 2023Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Trial of NT-I7 in COVID-19 (SPESELPIS)

Inclusion Criteria

Exclusion Criteria

A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes

Improving Post COVID-19 Syndrome With Hyperbaric Oxygen Treatments

Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID

A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease

Dime La VerDAD: Verify, Debunk, and Disseminate

Positron Emission Tomography (PET) Imaging of Thrombosis